Obesity

Manu Chakravarthy Roche

Biotech

Why Roche is 'really excited' about UCN2's obesity potential

Roche licensed the UCN2 analog after seeing preclinical data that “clearly suggests” it can cut weight while preserving muscle, Fierce has learned.

James Waldron Sep 3, 2026 10:47am

Genentech

Roche pens $2.5B pact for Hanmi’s muscle-conserving obesity drug

Aug 24, 2026 4:42am

Two aardvarks

After trimming headcount, Aardvark drops trials as wait drags on

Aug 12, 2026 9:03am

Karsten Munk Knudsen Novo Nordisk

Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth

Aug 7, 2026 9:08am

Doustdar

Novo CEO accepts ‘couple of setbacks,’ hunts for bolt-on deals

Aug 5, 2026 8:00am

Spiral helical welded steel pipe

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Aug 4, 2026 4:01pm